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Abstract
Background: Wilms tumor (WT) has a not completely elucidated pathogenesis. DNA copy number alterations (CNAs)
are common in cancer, and often define key pathogenic events. The aim of this work was to investigate CNAs in order
to disclose new candidate genes for Wilms tumorigenesis.
Results: Array-CGH of 50 primary WTs without pre-chemotherapy revealed a few recurrent CNAs not previously
reported, such as 7q and 20q gains, and 7p loss. Genomic amplifications were exclusively detected in 3 cases of WTs
that later relapsed, which also exhibited an increased frequency of gains affecting a 16.2 Mb 1q21.1-q23.2 region, losses
at 11p, 11q distal, and 16q, and WT1 deletions. Conversely, aneuploidies of chromosomes 13 and 19 were found only
in WTs without further relapse. The 1q21.1-q23.2 gain associated with WT relapse harbours genes such as CHD1L,
CRABP2, GJA8, MEX3A and MLLT11 that were found to be over-expressed in WTs. In addition, down-regulation of genes
encompassed by focal deletions highlighted new potential tumor suppressors such as CNKSR1, MAN1C1, PAQR7 (1p36),
TWIST1, SOSTDC1 (7p14.1-p12.2), BBOX and FIBIN (11p13), and PLCG2 (16q).
Conclusion: This study confirmed the presence of CNAs previously related to WT and characterized new CNAs found
only in few cases. The later were found in higher frequency in relapsed cases, suggesting that they could be associated
with WT progression.
Keywords: Wilms tumor, Array-CGH, Copy number alteration, CNA, Relapse, 1q21.1-q23.2 gain
Background
Wilms tumor (WT) is the most common type of malignant
renal cancer in childhood, with an incidence of 7.7 in 1
million children between 0 and 14 years of age in Western
populations [1, 2]. WTs exhibit a triphasic histology that
recapitulates the fetal kidney development [3, 4], and simi-
larly, gene expression profiling of isolated components
mimics the ongoing process of nephrogenesis [5].
Earlier cytogenetic studies of patients with WAGR
(MIM#194072), a syndrome characterized among others
by susceptibility to Wilms tumor, revealed constitutional
deletions on chromosome 11p13 affecting several con-
tiguous genes (reviewed in [6]) including WT1 [7, 8].
Latter on, cytogenetic and molecular studies of tumor
material from WT sporadic cases showed the presence
of somatic inactivating mutations or deletions of WT1
in up to 15 % of the cases [9–11].
Other somatic alterations have been causally related to
WT such as activating mutations in CTNNB1 [10, 12],
mutation/deletion of WTX [11, 13], and loss of imprint-
ing of IGF2 [9, 11, 14]. Recent molecular cytogenetic
studies of tumoral samples have identified other gen-
omic regions harboring genes supposedly associated with
WT development, as exemplified by HACE1 disruption
at 6q21 [15], and a 2q37 deletion encompassing the
miR-562 [16]. Somatic deletions of DIS3L2 have also
been identified in a group of WT, and germline
mutations of this gene results in Perlman syndrome
that also presents increased WT susceptibility [17].
More recently, recurrent somatic mutations in DROSHA
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(p.E1147K) as well as in other genes from the microRNA
biogenesis machinery (DGCR8, DICER1, XPO5 and
TARBP2) were found in up to 12 % of WTs [18–21].
Additionally, somatic mutations in SIX1/SIX2 were
found in a subgroup of WT presenting high prolifera-
tive potential [19]. Because SIX1 andDROSHAmutations
were found to be heterogeneous events within primary
tumors, both spatially and temporally, it was speculated
if their co-occurrence were positively associated
with tumor progression rather than tumor onset [22].
Somatic loss of heterozygosity (LOH) at 1p, 11q, 16q,
and 22q, and deletions at 12q and 18q were correlated
with an adverse outcome [23–26]. In clinical practice,
combined LOH of 1p and 16q are used as markers of
poor outcome for chemotherapy-naive tumors [23, 24];
however, they are detected in a very small subset of WT
patients. In addition to the description of 1p, 1q, 3p, 3q,
and 14q imbalances occurring at higher frequency in re-
lapsing tumors than in other tumors [27], copy number
gains at 1q have also been associated with poor progno-
sis in patients with favorable WT histology [28, 29]. A
study reported that 1q gain has limited prognostic value
for risk stratification in pre-treated WT [30]; however, it
has been questioned whether the sample size was large
enough and if the parameters used for defining 1q gain
were validated to draw this conclusion [31].
This study was designed to assess the genomic
copy number alterations profile (CNA) of WTs, aim-
ing to identify genetic markers associated with WT,
in particular those with clinical and prognostic
importance.
Results
Characterization of copy number alterations in Wilms
tumors
Array-CGH analysis detected a total of 350 CNAs in all
50 WT samples (mean of 7 CNAs per tumor genome),
ranging from focal rearrangements (70 kb–5 Mb) to
chromosome-arm alterations, and whole-chromosome
aneuploidies. Full and summarized descriptions of the
array-CGH data can be found in Additional file 1: Tables
S1 and S2. We performed statistical analyses comparing
WTs with and without relapse regarding the number,
distribution and type (gain, high-copy gain, loss, homo-
zygous loss) of CNAs. Genomic losses were more fre-
quent in the relapse group (p = 0.016, Fisher exact test)
than in the group without relapse, whereas high gains
(>5 copies) were detected exclusively in the group of tu-
mors from patients who relapsed (3 cases).
Typically, WTs present few alterations indicating low
chromosomal instability. The log2 ratios for most alter-
ations were in a range consistent with heterozygous
losses or gains (>0.5 or <−0.5), suggestive of a low level
of intra-tumor heterogeneity. As an example, Fig. 1a
shows the array-CGH results of four Wilms tumors;
each lane shows the copy number profile of all chromo-
somes for one sample. Figure 1b summarizes the copy
number findings detected in the WT cohort and their
respective frequencies, showing the full cohort (upper
panel) as well as tumors grouped according to the oc-
currence of relapse (bottom panel). Gains affecting 1q
were observed in >50 % of the tumors, but frequent
CNAs (>15 % of the WT group) included gains of 7q
and 20q, and losses at 1p, 7p, 11q, and 16q, in addition
to whole-chromosome aneuploidies of 6, 8, 12, and 20
(gains), and 22 (losses).
WTs derived from patients who later relapsed carried
few genomic alterations detected in higher frequency
than the group without relapse, such as 1q gain (with a
peak at 1q proximal) and losses at 11p (with a peak
encompassing the WT1 gene), 11q distal, and 16q
(Fig. 1b, bottom panels). Conversely, aneuploidies of
chromosomes 13 and 19 (gains) were exclusively detected
in the WTgroup without relapse.
Recurrent chromosomal alterations e minimum
common regions
Table 1 describes six recurrent (frequency >15 % in the
entire WT group) chromosomal rearrangements and
their frequencies according to relapse status.
Focal 1q proximal gains were found in 63 % of the
WT relapse group and in a significantly lower propor-
tion in the WTs without relapse group (35.3 %). Focal
losses encompassing either the WT1 or WTX (AMER1)
genes (Additional file 2: Figure S1) occurred in 12 and
6 % of WTs, respectively. The frequency of WT1 dele-
tions was significantly higher in WTs that later relapse
than in the group without relapse (21 versus 6.4 %); one
tumor from a patient who relapsed was found to carry
both WTX and WT1 deletions.
Twelve minimum common regions (MCRs) of chromo-
somal alterations detected in at least two WTs were
identified and are described in Table 2.
We performed a comparative analysis of differential
CNAs looking for the smallest common regions of
aberrations that were more frequent in each WT
group (tumors derived from patients who later pre-
sented relapse or not). In the manual curated ana-
lysis, we detected a region of 44.5 Mb at 1q21.1q31.1
(#chr1:144,053,035-188,589,610; GRCh37) that exhib-
ited a higher frequency of gain in the relapse group than
in the non-relapse group. This region encompasses the
MCR of high-copy number gain at 1q21.1q23.2
(16.2 Mb), which was detected in two of the relapse
WTs (WT1104 and WT1232); gains of two of the af-
fected genes, S100A4 and NOTCH2 were validated by
qPCR in several tumors (Additional file 3: Figure S2).
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Fig. 1 (See legend on next page.)
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Additionally, we narrowed 14q genomic deletions to a
segment at 14q24.1q32.12 common to four WTs: one
relapsed tumor (WT1232), and three non-relapse
cases (WT095, WT246, and WT321).
Focal chromosomal rearrangements
Two small regions exhibiting high-copy gains (log2
ratio >1.4 indicating >5 copies) were detected in one
relapsed WT (WT1104), and validated by qPCR: a
2.4 Mb 1p31.1 amplification (#chr1:80,765,303-83,606,627;
GRCh37) containing only LPHN2 (Fig. 2a, b, and c), and a
300 Kb amplification at 2q24.1 (#chr2:158,834,824-159,
135,178; GRCh37), encompassing only the UPP2 and
CCDC148 genes (Fig. 2a, d, and e).
Regarding small genomic losses, the 1.6 Mb deletion
at 6q16.3q21 (#chr6:103,820,062-105,461,750; GRCh37)
encompassed only the genomic sequences of the HACE1,
LINC00577, and LIN28B genes (Fig. 3a, b, and c), detected
in two non-relapse WTs (WT329 and WT1070), neither
carrying WT1 or WTX deletions. Another validated focal
CNA detected in one tumor (WT201) was the 825 kb
homozygous deletion at 11p14.1p14.2 (#chr11:26,688,179-
27,513,817; GRCh37), harbouring BBOX, among others
genes (SLC5A12, FIBIN, CCDC34, LGR4) (Fig. 3d, e, and f).
Gene expression analysis
To evaluate the expression of genes affected by CNAs in
these WTs, we selected a set of 90 genes mapped in
MCRs, focal rearrangements, and the 1q21.1q23.2 region
associated with relapse. There were 35 (39 %) differentially
expressed genes between WTs and differentiated kidneys
(fold-change ≥|2|; p ≤0.05), with only 16 (46 %) exhi-
biting a concordant pattern of gene expression and
type of CNA (see Table 3). Unsupervised hierarchical
clustering (Additional file 4: Figure S3) based on the
expression pattern of this set of 16 genes discriminated
all WT samples from all but one differentiated kidneys
(DKs); however, this group of genes was not able to
discriminate WT samples with or without later relapse.
Eleven genes located at genomic deletions were
found to be down-regulated in WTs when compared
with DKs, nine of them mapped in MCRs: MAN1C1,
CNKSR1, and PAQR7 (1p36); INPP5D and ECEL1
(2q37); SOSTDC1, TWIST1 and AHR (7p14.1p12.2);
and PLCG2 (16q22.1q24.3). The remaining two down-
regulated genes, BBOX and FIBIN, were mapped in a
homozygous 11p13 deletion detected in a single tumor.
Regarding those genes located at copy number gains, five
of them, mapped at the 1q21.1q23.2 gain (more frequently
detected in relapsed samples), were found to be over-
expressed in WTs compared with DKs: CHD1L, CRABP2,
GJA8,MEX3A, andMLLT11.
Discussion and conclusions
In this study, WTs exhibited a relatively small number of
CNAs indicating low chromosomal instability, in accord-
ance with previous reports of favourable histology WTs.
Primary WTs that later relapse are supposedly more ag-
gressive as they are resistant to chemotherapeutic treat-
ments. The fact that these tumors displayed more
chromosome alterations and higher gains is in part sup-
ported by findings of a high level CNAs found in the more
aggressive diffuse anaplastic WT subtype [32]. Most of the
chromosome alterations from this study has already been
described by previous studies, such as 1q gain, and 11q
and 16q losses [23, 27, 30] as well as alterations reported
in low frequency, including the 2q37 deletion [16], and
the 6q21 deletion [15]. However, a few CNAs detected in
frequencies >15 % were reported here for the first time in
WT, including 7q and 20q gains, and 7p loss.
Table 1 Six recurrent chromosomal rearrangements (frequency >15 % in the entire WT group) and microdeletions of WT1 and WTX
genes according to the relapse status
WT group Recurrent rearrangements
(chromosome arm/focal)
Whole-chromosome aneuploidies Microdeletion of known
WT genes
1p(−) 1q(+) 7p(−) 7q(+) 11q(−) 16q(−) chr6 chr8 chr12 chr20(+) chr22(−) WT1 WTX (AMER1)
No-relapse (n = 31) 5 11 7 6 7 6 7 6 5 5 2 2 2
frequency 16.1 % 35.5 % 22.6 % 19.3 % 22.6 % 19.3 % 6.4 % 6.4 %
Relapse (n = 19) 3 12 4 5 6 6 3 3 4 2 1 4 1
frequency 15.8 % 63.2%a 21.0 % 26.3 % 31.6 % 31.6 % 21.0%a 5.3 %
aSignificant differences between WTs derived from patients who later relapsed or not
(See figure on previous page.)
Fig. 1 Copy number profiles of sporadic Wilms tumors. All chromosomes are displayed from the short to the long arms. Images adapted from
Nexus Copy Number software, Biodiscovery. a Array-CGH profile of four selected Wilms tumor samples. b Global profile of copy number alterations
(CNA) and respective frequencies in the 50 WT samples (upper panel) and the CNA distribution according to the occurrence of relapse (bottom panels).
Genomic gains are indicated by blue bars, losses by red bars and yellow boxes mark the alterations detected in higher frequency or exclusively in each
group; relapsed patients (R+), non-relapsed patients (R-)
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In this study, the blastemal component of WT was
micro-dissected before DNA extraction. Eventually, this
procedure could minimize findings related to tumor het-
erogeneity that have been described in pediatric tumors
[33], at least those related to cell differentiation. Unfor-
tunately, the array-CGH platform used in this study does
not allow allelic identification, impeding a careful as-
sessment of the presence of intratumor heterogeneity at
low levels.
The association between chromosomal alterations and
cancer recurrence in patients with WT has been suggested
by some publications, all of which share similar findings
[25, 27, 34, 35]. In our samples, the 1q gain was found in
63.2 % of the tumors that later relapse in comparison with
35.5 % of the non-relapsed WTs. This higher frequency
of 1q gain, compared to previous studies, can be ex-
plained by the fact that in our tumor series only the
blastemal component were assessed. A specific genomic
segment at 1q21.1q31.3 has been associated with WT
relapse [28, 36], and in the present work this region was
narrowed to a 16.2 Mb segment at 1q21.1q23.2. Five
genes mapped within this 1q21.1q23.2 segment were
Fig. 2 Genomic amplifications detected in one Wilms Tumour. a Genomic array-CGH profile of one Wilms tumor (WT1104) showing amplifications
located in 1p and 2q (red boxes). b In the chromosome 1 ideogram, the blue box marks a 2.4 Mb 1p31.1 amplification containing only one coding
gene, LPHN2, and underneath is the array-CGH profile of the genomic region. c DNA copy number evaluation of the LPHN2 by qPCR; the blue bar
represents the tumor sample and the white bar the control. Each bar represents the average copy number of 3 replicates, and the error bars show
the standard deviation (adapted from CopyCaller software, Applied Biosystems). d In the chromosome ideogram, the blue box marks a 300 kb
amplification at 2q24.1, and underneath is the array-CGH profile of the genomic region. e DNA copy number evaluation of the UPP2 by qPCR; the
blue bars represent three tumor samples and the white bar represents the control. Each bar represents the average copy number of 3 replicates,
and the error bars show the standard deviation (adapted from CopyCaller software, Applied Biosystems)
Table 2 Twelve minimum common regions of chromosomal







#chr1:23,362,908-26,746,259 1p36.12p36.11 3.38 deletion
#chr1:144,824,185-161,067,947 1q21.1q23.2 16.24 amplicon
#chr2:224,323,183-236,091,182 2q37 11.77 deletion
#chr4:114,506,621-115,974,843 4q26 1.47 deletion
#chr7:39,742,350-49,836,566 7p14.1p12.2 10.10 deletion
#chr7:133548462-158674912 7q33q36.3 25.13 gain
#chr10:125,525,789-135,524,747 10q26.13q26.3 10.00 gain
#chr11:33,713,698-36,511,648 11p13p12 2.80 deletion
#chr11:111,359,499-120,743,656 11q23.1q23.3 9.38 deletion
#chr14:19,373,243-34,950,464 14q11.1q13.1 15.58 gain
#chr14:68,882,507-92,887,911 14q24.1q32.12 24.01 deletion
#chr16:71,201,074-90,294,753 16q22.1q24.3 19.09 deletion
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found to be up-regulated in WTs compared with DKs
(CHD1L, CRABP2, GJA8, MEX3A and MLLT11) but not
between relapse and no-relapse WT. CRABP2 higher
expression also had a weak association with high stage
WTs [37]. MLLT11 has a role with leukemogenesis
[38, 39], and CHD1L is over-expressed in hepatocellular
carcinomas [40].
Combined LOH of 16q and 1p is a known marker of
poor prognosis; indeed, we found a higher frequency of
16q deletion (31.6 %) in relapsed cases when compared
with non-relapsed cases (19.3 %), and narrowed to a
19 Mb segment at 16q22.1q24.3. We also found deletions
affecting WT1 in 12 % of all cases detected with a signifi-
cantly higher frequency in the relapse group. Although
these genomic features could be useful as prognostic
indicators for blastemal predominance, they were very
infrequent events, therefore adding little to the ability
to distinguish patients with different outcomes.
Losses of 14q have been shown to have a borderline
association with tumor stages III and IV [27] suggesting
that genes located in this chromosome region have the
potential to be involved in tumor progression. WTs here
studied are mostly stages III and IV tumors, and the de-
tection of 14q deletions in four samples allowed to narrow
this genomic deletion to a segment at 14q24.1q32.12
(one relapsed and three non-relapse cases).
Other MCRs of new genomic deletions highlighted
few genes with a concordant profile with gene expression,
Fig. 3 Genomic deletions detected in Wilms tumours. a Genomic array-CGH profile of one Wilms tumour (WT329) showing the heterozygous loss
detected at 6q16.3q21 (red box). b In the chromosome 6 ideogram, the red bar marks a 1.6 Mb microdeletion, and underneath is the array-CGH
profile of the region. c DNA copy number evaluation of the HACE1 by qPCR; the red bar represents the tumour sample and the white bar represents
the control. Each bar represents the average copy number of 3 replicates, and the error bars show the standard deviation (adapted from CopyCaller
software, Applied Biosystems). The results show the presence of a single copy of the HACE1 sequence in the tumour genome compared to
controls. d Genomic array-CGH profile of one Wilms tumour (WT201) showing the homozygous deletion detected at 11p13p12 (red box). e In
the chromosome 11 ideogram, the red bar marks an 825 kb homozygous deletion, and underneath is the array-CGH profile of the region. f DNA copy
number evaluation of the BBOX by qPCR; the red bars represent the tumours samples and the white bar represents the control. Each bar represents the
average copy number of 3 replicates, and the error bars show the standard deviation (adapted from CopyCaller software, Applied Biosystems)
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particularly CNKSR1, MAN1C1 and PAQR7 at 1p36, and
TWIST1 and SOSTDC1 at 7p14.1p12.2, the later already
suggested as tumor suppressor in WT [41]. The analysis
of other small alterations of high amplitude in copy
number change disclosed new candidate genes poten-
tially associated with WT such as LPHN2, UPP2, BBOX
and FIBIN. Only BBOX and FIBIN, identified in a
homozygous deletion at 11p13, exhibited a concordant
down-regulated pattern of gene expression when con-
sidering the entire WT group; therefore, both genes ap-
pear as candidate tumor suppressor genes for WT but
need further studies to confirm their role.
We are aware that this study has limitations. The set
of genes which expression were compared to differenti-
ated kidneys, not an ideal control, came from alterations
found in only one or few tumors, thus explaining the ob-
served low level of agreement between CNAs and ex-
pression pattern. Additionally, we do not have tested
other patient’s tissues to exclude the possibility that part
of the detected CNAs were germline alterations. However,
all CNAs were checked in the Database of Genomic Vari-
ants and none of them was found to be common changes.
In summary, most of the detected CNAs in this study
were described by previous works. However, the present
work identified that genomic amplifications and higher
number of genomic losses occur in tumors that later re-
lapsed. Additionally, these tumors exhibited an increased
frequency of a gain of a 16.2 Mb segment at
1q21.1q23.2, and losses at 11p, 11q distal, and 16q,
together with WT1 deletions. Conversely, aneuploidies
of chromosomes 13 and 19 (whole-chromosome gains)
were exclusively detected in WTs without relapse, sug-
gesting that these are good prognosis markers.
The CNAs affected the expression of few genes (over-
expression of CHD1L, CRABP2, GJA8, MEX3A and
MLLT11 and down-regulation of CNKSR1, MAN1C1,
PAQR7, TWIST1, SOSTDC1, BBOX and FIBIN) that
could have an oncogene or tumor suppressor role in
WT. We stress that although the studied cohort of
WTs is small, most of the genomic regions here identi-
fied have been described in WT by others, reinforcing
that they should be investigated in depth to disclose
the possible roles of the affected genes in Wilms
tumorigenesis.
While isolated genes can account for selection of
specific chromosome imbalances (drivers), another al-
ternative theory, applying an evolutionary perspective,
hypothesizes that the different karyotypes with specific
combinations of chromosome alterations could result
in slightly different tumor subtypes. The high rate of
variation within a tumor generates tumor sub-clones
with different phenotypic progression, as exemplified
by the acquisition of resistance to chemotherapy or the
metastatic growth [42, 43]. For instance, in the case of
WT, this process could also be reflected by the hetero-
geneous histology found within each tumor. Some pre-
liminary data reported intra-tumor heterogeneity in
70 % of the WT cases albeit they may also share some
common copy number changes [44]. Most of the alter-
ations we found are shared by WTs from other studies,




Samples of sporadic primary WTs were obtained from
50 patients enrolled in the National Wilms tumor Study
5 (NWTS-5, Children Oncology Group). The group is
enriched for WTs stages III and IV, which characteristics
have been described [45]. Tumors analysed were not
subjected to neoadjuvant chemotherapy; 31 of these pa-
tients exhibited no relapse after a minimum of 3 years of
follow-up. All samples were obtained with informed
consent. This work was conducted in accordance with
the principles of the Declaration of Helsinki and was ap-
proved by the A. C. Camargo Cancer Center ethics com-
mittee under number CEP 764/06.
Comparative genome hybridization based on microarrays
(array-CGH)
We performed comparative genomic hybridization
based on microarrays in a commercial whole-genome
180 K platform containing 180,000 oligonucleotide
Table 3 Sixteen differentially expressed genes in the group of
Wilms tumours compared to differentiated kidneys which
exhibited a concordant pattern of copy number alteration (CNA)
Gene name Fold change Type of CNA
CNKSR1 −2.30* 1p36.12p36.11 deletion
MAN1C1 −7.37** 1p36.12p36.11 deletion
PAQR7 −10.71** 1p36.12p36.11 deletion
CHD1L 3.18** 1q21.1q23.2 gain
CRABP2 31.59** 1q21.1q23.2 gain
GJA8 25.48* 1q21.1q23.2 gain
MEX3A 10.28** 1q21.1q23.2 gain
MLLT11 14.04** 1q21.1q23.2 gain
DNMT3A 2.42** 2p25.3p11.2 gain
INPP5D −2.56* 2q37 deletion
AHR −9.62** 7p14.1p12.2 deletion
SOSTDC1 −21.39** 7p14.1p12.2 deletion
TWIST1 −3.26* 7p14.1p12.2 deletion
BBOX1 −39.84* 11p13p12 homozygous loss in one WT
FIBIN −8.10* 11p13p12 homozygous loss in one WT
PLCG2 −8.96* 16q22.1q24.3 deletion
*p < 0.05, **p < 0.01
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probes (Agilent Technologies; design 22060). Reference
DNA was a commercially available human pool of sam-
ples from healthy donors (Promega). Briefly, samples
were labelled with Cy3- or Cy5-deoxycytidine triphos-
phates by random priming, and purification, hybridization
and washing were performed as recommended by the
manufacturer. Scanned images of the arrays were
processed using Feature Extraction 10.7.3.1 software
(Agilent Technologies).
Array-CGH analysis was performed using Nexus Copy
Number software 7.0 (Biodiscovery) with the FASST2
segmentation algorithm, according to the following set-
tings: minimum of 5 consecutive probes (effective
resolution of ~70 Kb for CNA calling), significance
threshold set at 10−8, and threshold log2 Cy3/Cy5 of 0.3
and 1.4 for gain or high copy gain (indicating >5 copies
of the genomic sequence, and hereafter named amplifi-
cation), respectively, and −0.3 and −1.1 for loss and
homozygous loss, respectively. All copy number vari-
ants reported in the Database of Genomic Variants
(DGV; http://dgv.tcag.ca/dgv/app/home) were ex-
cluded, as well data from sex chromosomes; the X-
linked gene AMER1 (WTX) was analysed separately.
The minimum common regions (MCRs) of recurrent
CNAs were obtained by implementing the global fre-
quency statistical approach of the STAC method (Sig-
nificance Testing for Aberrant Copy Number [46]).
Data were evaluated iregarding the total number of
CNAs and the numbers of gains, losses, amplifications,
and homozygous losses. Genes affected by copy num-
ber changes were annotated using the Genome
browser UCSC (http://genome.ucsc.edu/). Statistical
analyses were performed using the software GraphPad
PRISM 5.
DNA copy number validation by real-time quantitative
PCR (qPCR)
To validate 9 focal CNAs (<5 Mb), we performed qPCR
using 9 TaqMan probes (see Additional file 5: Table S3)
on a 7500 Fast Real-time quantitative PCR System
(Applied Biosystems). Copy number determinations
were performed for selected targets using TaqMan
Gene Copy Number Assays (Applied Biosystems). The
assays contained a FAM-labelled TaqMan probe for
the target gene and a VIC-labelled TaqMan probe for
the reference gene (RNaseP). The reference sample or
calibrator was a commercially available human genomic
DNA (Promega). The results were analysed using Copy-
Caller 1.0 software (Applied Biosystems). The relative
number of DNA copies for each probe was determined by
the DDCt ((FAM Ct–VIC Ct) sample–(FAM Ct–VIC Ct)
calibrator) method, which assumes that the calibrator
DNA has two copies of the reference gene.
Gene expression analysis by reverse transcription
quantitative real-time PCR (RT-qPCR)
We selected 90 genes for gene expression evaluation by
RT-qPCR (Additional file 6: Table S4) that were affected
by recurrent copy number changes in our cohort of
WTs. Total RNA samples were enzymatically converted
into first-strand cDNA using an RT2 First Strand cDNA
Kit (Qiagen). We evaluated 36 WT blastemal enriched
samples and six differentiated kidneys (DK) used as con-
trols. These control samples constituted the cortex of dif-
ferentiated kidneys from nephrectomies of WT patient’s
macrodissected after evaluation of hematoxilin-eosin sec-
tions. We used a SYBR-green based customized array RT2
qPCR Primer Customized Assay (Qiagen Technologies)
following the manufacturer’s protocol. RT-qPCR was per-
formed in an ABI Prism 7900HT Fast Real-time Sequence
Detection System (Life Technologies, Foster City, CA).
ACTB, GAPDH, and HPRT1 were tested as reference
genes, and the two most stable genes (as determined by
geNorm [47]), namely, ACTB and GAPDH, were used for
normalization in the expression analysis. The array data
were analysed by SDS and RQ manager (Life Technolo-
gies), and gene expression normalization was calculated
using the 2ΔCq method. Genes were considered differen-
tially expressed between groups (WTs and DKs) if the fold
change was ≥|2| with p-value ≤0.05 (student t-test).
Additional files
Additional file 1: Table S1. Full CNA data identified by array-CGH in the
50 Wilms tumor samples. CNA calling was performed using the software
Nexus Copy Number 7.0 (Biodiscovery). Table S2. Array-CGH data summary
of Wilms tumor samples: total number of copy number alteration, number
of each type of copy number event (gain, loss, high-copy gain, and
homozygous loss), and statistical analysis. (XLS 872 kb)
Additional file 2: Figure S1. DNA copy number evaluation showing
focal and homozygous losses of the WT1 (A) and WTX (B) genes by
qPCR; the red bars represent tumour samples and the white bar
represents the control. Each bar represents the average copy number of
3 replicates, and the error bars show the standard deviation (adapted
from CopyCaller software, Applied Biosystems). (TIF 226 kb)
Additional file 3: Figure S2. DNA copy number evaluation showing
amplification of S100A4 (A) and NOTCH2 (B) genes at 1q21.1-q23.2 in
several tumours by qPCR; the blue bars represent tumour samples and
the white bar represents the control. Each bar represents the average copy
number of 3 replicates, and the error bars show the standard deviation
(adapted from CopyCaller software, Applied Biosystems). (TIF 349 kb)
Additional file 4: Figure S3. Unsupervised hierarchical clustering using
Pearson’s correlation, and complete linkage of 36 Wilms tumour (WTs)
and 6 differentiated kidney (DKs) samples based on 16 differently expressed
genes (values were log2-transformed). Only genes with expression detected
in more than 80 % of the samples were considered. Bootstrap resampling
was performed to assess cluster reliability, and the results are represented
by the coloured lines of the dendrogram (black line indicates 90–100 %
reliability). Differentiated kidney samples are marked in blue, and Wilms
Tumour samples are coloured pink (light pink are non-relapse samples, and
dark pink are relapse samples). Columns and rows represent samples and
genes, respectively; red, upregulated, and green, down-regulated genes.
(TIF 425 kb)
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Additional file 5: Table S3. List of genes selected for copy number
validation of 9 focal rearrangements using real-time quantitative PCR
(qPCR) with TaqMan Gene Copy Number assays. (DOC 34 kb)
Additional file 6: Table S4. Description of 90 genes that were selected
for gene expression analysis in the group of Wilms tumors using a
SYBR-green based customized array RT2 qPCR Primer Customized Assay
(Qiagen Technologies). Description of the genes selected as controls for
gene expression analysis in the group of Wilms tumors using a the
SYBR-green based customized array RT2 qPCR Primer Customized Assay
(Qiagen Technologies). (XLS 56 kb)
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